AMKL
MCID: MGK001
MIFTS: 55

Megakaryocytic Leukemia (AMKL) malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Megakaryocytic Leukemia

Aliases & Descriptions for Megakaryocytic Leukemia:

Name: Megakaryocytic Leukemia 38 12 14
Acute Megakaryoblastic Leukemia 12 50 56
Acute Megakaryocytic Leukemias 12 69
Acute Megakaryocytic Leukemia 50 56
Acute Myeloid Leukemia M7 50 56
Aml M7 50 56
Amkl 50 56
Acute Megakaryoblastic Leukaemia, Fab M7 12
Acute Megakaryoblastic Leukemia, Fab M7 12
Acute Myeloblastic Leukemia Type 7 50
Leukemia, Megakaryoblastic, Acute 42
Megakaryoblastic Leukemia, Acute 13
Megakaryoblastic Leukemia Acute 52
Leukemia, Myelocytic, Acute 69
Megakaryocytic Myelosis 12
Thrombocytic Leukaemia 12

Characteristics:

Orphanet epidemiological data:

56
acute megakaryoblastic leukemia
Inheritance: Not applicable; Age of onset: Childhood;

Classifications:



External Ids:

Disease Ontology 12 DOID:8761
ICD10 33 C94.2 C94.20
ICD9CM 35 207.2
MeSH 42 D007947
NCIt 47 C3170
Orphanet 56 ORPHA518
ICD10 via Orphanet 34 C94.2
UMLS 69 C0023462

Summaries for Megakaryocytic Leukemia

Disease Ontology : 12 A leukemia that derives from blood-forming tissue in which megakaryocytes proliferate in the bone marrow and circulate in the blood in large numbers.

MalaCards based summary : Megakaryocytic Leukemia, also known as acute megakaryoblastic leukemia, is related to acute megakaryoblastic leukemia in down syndrome and acute megakaryoblastic leukemia without down syndrome, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Megakaryocytic Leukemia is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and bone marrow, and related phenotypes are cellular and cardiovascular system

Wikipedia : 71 Acute megakaryoblastic leukemia (AMKL) is a form of leukemia where a majority of the blasts are... more...

Related Diseases for Megakaryocytic Leukemia

Diseases related to Megakaryocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Related Disease Score Top Affiliating Genes
1 acute megakaryoblastic leukemia in down syndrome 12.2
2 acute megakaryoblastic leukemia without down syndrome 12.0
3 leukemia 10.7
4 choledochal cyst 10.2 CSF2 IL3
5 mild phosphoribosylpyrophosphate synthetase superactivity 10.2 MKL1 RBM15
6 pyloric stenosis, infantile hypertrophic, 4 10.2 GATA1 IL3
7 febrile seizures, familial, 2 10.2 CSF2 IL3
8 mental retardation, autosomal dominant 37 10.2 CSF2 IL3
9 scleroderma, familial progressive 10.2 CSF2 IL3
10 necrotizing gastritis 10.2 CSF2 IL3
11 aniseikonia 10.2 CBS CSF2
12 von hippel anomaly 10.1 IL3 RUNX1
13 down syndrome 10.1
14 subclavian artery aneurysm 10.0 CSF2 ITGA2B
15 dic in newborn 10.0 CSF2 IL3 KITLG
16 craniofrontonasal dysplasia 10.0 GATA1 THPO
17 thrombocytopenia, congenital amegakaryocytic 10.0 IL3 THPO
18 sinusitis 10.0 CSF2 IL3 KITLG
19 acute dacryoadenitis 10.0 CSF2 IL3 KITLG
20 myelofibrosis 10.0
21 phosphoserine phosphatase deficiency 10.0 GATA1 IL3 RUNX1
22 peroxisome biogenesis disorder 7a 9.9 CSF2 IL3 KITLG RUNX1
23 granulomatous hepatitis 9.9 CSF2 IL3 THPO
24 mental depression 9.9 ITGA2B THPO
25 severe nonproliferative diabetic retinopathy 9.9 ITGA2B THPO
26 myeloproliferative neoplasm 9.9 ITGA2B RUNX1 THPO
27 intestinal impaction 9.8 IL3 KITLG THPO
28 membranoproliferative glomerulonephritis 9.8 CSF2 ITGA2B THPO
29 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 9.8 IL3 THPO
30 pulmonary hypertension 9.8
31 acute leukemia 9.8
32 hematopoietic stem cell transplantation 9.8
33 hepatitis 9.8
34 hypoxia 9.8
35 sarcoma 9.8
36 bulbospinal polio 9.8 ITGA2B KITLG THPO
37 tracheal disease 9.8 GATA1 IL3 ITGA2B THPO
38 basilar artery insufficiency 9.8 GATA1 IL3 ITGA2B THPO
39 cytokine receptor deficiency 9.7 CSF2 IL3 KITLG THPO
40 osteoarthritis 9.7 CSF2 IL3 KITLG THPO
41 pneumonia 9.7
42 malignant teratoma 9.7
43 mediastinitis 9.7
44 vasculitis 9.7
45 beckwith-wiedemann syndrome 9.7
46 myeloid sarcoma 9.7
47 myeloid leukemia 9.7
48 diabetes insipidus 9.7
49 periostitis 9.7
50 acquired central diabetes insipidus 9.7

Comorbidity relations with Megakaryocytic Leukemia via Phenotypic Disease Network (PDN):


Acquired Thrombocytopenia Deficiency Anemia
Neutropenia

Graphical network of the top 20 diseases related to Megakaryocytic Leukemia:



Diseases related to Megakaryocytic Leukemia

Symptoms & Phenotypes for Megakaryocytic Leukemia

UMLS symptoms related to Megakaryocytic Leukemia:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Megakaryocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 CSF2 GATA1 ITGA2B JAK3 KITLG MKL1
2 cardiovascular system MP:0005385 9.95 ITGA2B KITLG MKL1 PTEN RUNX1 CSF2
3 hematopoietic system MP:0005397 9.91 RBM15 RUNX1 THPO CSF2 GATA1 ITGA2B
4 immune system MP:0005387 9.81 CSF2 GATA1 ITGA2B JAK3 KITLG PTEN
5 embryo MP:0005380 9.8 CSF2 GATA1 ITGA2B KITLG PTEN RUNX1
6 integument MP:0010771 9.43 CSF2 GATA1 KITLG MKL1 PTEN RUNX1
7 neoplasm MP:0002006 9.02 CSF2 KITLG PTEN RBM15 RUNX1

Drugs & Therapeutics for Megakaryocytic Leukemia

Drugs for Megakaryocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
3
Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Antilymphocyte Serum Phase 4,Phase 2,Phase 1
9
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
10
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
11
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
12
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
13
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
14
Idarubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 58957-92-9 42890
15
Mesna Approved Phase 3 3375-50-6 598
16
Amsacrine Approved Phase 3 51264-14-3 2179
17
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
18
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
19
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
20
Clofarabine Approved, Investigational Phase 2, Phase 3, Phase 1 123318-82-1 119182
21
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
22
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
23
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
24
Hydroxyurea Approved Phase 3 127-07-1 3657
25
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
26
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
27
Azacitidine Approved, Investigational Phase 2, Phase 3, Phase 1 320-67-2 9444
28
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
29
Carmustine Approved Phase 3 154-93-8 2578
30
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
31
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
32
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
33
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
34
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
35
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
36
Fluconazole Approved Phase 3 86386-73-4 3365
37
Cyproheptadine Approved Phase 3 129-03-3 2913
38
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
39
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
42
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
43
Butyric Acid Experimental Phase 3 107-92-6 264
44 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
45 Analgesics Phase 3,Phase 2,Phase 1
46 Antibodies Phase 3,Phase 2
47 Antibodies, Monoclonal Phase 3,Phase 2
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antimetabolites Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 198)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3
3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3
4 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3
6 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
7 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3
8 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Unknown status NCT02241031 Phase 2, Phase 3
9 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3
10 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3
12 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3
13 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3
14 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
15 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3
16 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3
17 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3
18 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3
19 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3
20 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3
21 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3
22 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3
23 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3
24 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3
25 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
26 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3
27 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02085408 Phase 3
28 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
31 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2
32 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2
33 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2
34 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2
35 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
36 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2
37 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
38 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2
39 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
40 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
41 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2
42 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2
44 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2
45 S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00093418 Phase 2
46 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2
47 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2
48 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2
49 Vorinostat in Treating Patients With Acute Myeloid Leukemia Completed NCT00305773 Phase 2
50 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia Completed NCT00602771 Phase 2

Search NIH Clinical Center for Megakaryocytic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Megakaryocytic Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, megakaryoblastic, acute

Genetic Tests for Megakaryocytic Leukemia

Anatomical Context for Megakaryocytic Leukemia

MalaCards organs/tissues related to Megakaryocytic Leukemia:

39
Bone, Myeloid, Bone Marrow, Monocytes, Liver

Publications for Megakaryocytic Leukemia

Articles related to Megakaryocytic Leukemia:

(show top 50) (show all 115)
id Title Authors Year
1
CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells. ( 27762064 )
2016
2
Acute megakaryocytic leukemia: What have we learned. ( 26228843 )
2015
3
Megakaryocytic leukemia 1 directs a histone h3 lysine 4 methyltransferase complex to regulate hypoxic pulmonary hypertension. ( 25646298 )
2015
4
Megakaryocytic leukemia 1 (MKL1) regulates hypoxia induced pulmonary hypertension in rats. ( 24647044 )
2014
5
Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia. ( 25498456 )
2014
6
Extramedullary Tumor of Cerebral Falx: An Unusual Presentation of Acute Megakaryocytic Leukemia. ( 24663070 )
2014
7
Relapse of acute megakaryocytic leukemia as hepatic myeloid sarcoma after allogeneic haploidentical hematopoietic stem cell transplantation. ( 24916785 )
2014
8
Hemophagocytosis in acute megakaryocytic leukemia: hemophagocytosis or emperipolesis? ( 23823115 )
2013
9
Case study interpretation-New Orleans: case 1. Extramedullary acute megakaryocytic leukemia. ( 23283835 )
2013
10
Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia. ( 23874683 )
2013
11
Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia. ( 23533276 )
2013
12
Megakaryocytic leukemia 1 (MKL1) ties the epigenetic machinery to hypoxia-induced transactivation of endothelin-1. ( 23625963 )
2013
13
Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia. ( 22294728 )
2012
14
Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia. ( 22936051 )
2012
15
A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy. ( 22110660 )
2011
16
Congenital acute megakaryocytic leukemia. ( 22557786 )
2011
17
Acute megakaryocytic leukemia (AMKL,FAB;M7) with Beckwith-Wiedemann syndrome. ( 20589645 )
2010
18
A rare case of GATA1 negative chemoresistant acute megakaryocytic leukemia in an 8-month-old infant with trisomy 21. ( 20108342 )
2010
19
Unbalanced chromosome 1 abnormalities leading to partial trisomy 1q in four infants with Down syndrome and acute megakaryocytic leukemia. ( 19228396 )
2009
20
Hypercalcemia in pediatric acute megakaryocytic leukemia: case report and review of the literature. ( 19415024 )
2009
21
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. ( 19638627 )
2009
22
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. ( 18094719 )
2008
23
Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. ( 17988992 )
2007
24
Segregation of megakaryocytic or erythroid cells from a megakaryocytic leukemia cell line (JAS-R) by adhesion during culture. ( 17383723 )
2007
25
Massive periosteal reaction a presenting feature of acute megakaryocytic leukemia. ( 18045316 )
2007
26
Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis. ( 17916755 )
2007
27
Histologic and molecular characterizations of megakaryocytic leukemia in mice. ( 16219351 )
2006
28
[The role of GATA1 mutation in acute megakaryocytic leukemia]. ( 17176883 )
2006
29
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. ( 16249385 )
2006
30
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. ( 16123215 )
2006
31
Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders. ( 15902283 )
2005
32
Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). ( 15191953 )
2005
33
Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. ( 16010437 )
2005
34
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. ( 15687366 )
2005
35
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. ( 16037387 )
2005
36
Inhibition by Rho-kinase and protein kinase C of myosin phosphatase is involved in thrombin-induced shape change of megakaryocytic leukemia cell line UT-7/TPO. ( 15567063 )
2005
37
Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. ( 15317736 )
2004
38
Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. ( 15307108 )
2004
39
AML1 overexpression and/or mutations should be checked in trisomy 21 patients with megakaryocytic leukemia. ( 12835737 )
2003
40
Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. ( 12393509 )
2003
41
Severe megakaryocytic dysplasia in a case of myelodysplasia progressing to acute megakaryocytic leukemia presenting with dic(1;16)(q21;p13.3) and t(1;22)(p13;q13). ( 14553955 )
2003
42
Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions. ( 12225399 )
2002
43
Acute megakaryocytic leukemia in essential thrombocythemia: an unusual evolution? ( 12366715 )
2002
44
Criteria for diagnosis of acute megakaryocytic leukemia. ( 11263442 )
2001
45
Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. ( 11344311 )
2001
46
The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. ( 10616523 )
2000
47
The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages. ( 10811458 )
2000
48
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. ( 11001891 )
2000
49
Simultaneous detection of platelet-associated antigen and platelet peroxidase on buffy coat cells from bone marrow in two patients with pediatric acute megakaryocytic leukemia. ( 10524465 )
1999
50
Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. ( 10340400 )
1999

Variations for Megakaryocytic Leukemia

ClinVar genetic disease variations for Megakaryocytic Leukemia:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GATA1 NM_002049.3(GATA1): c.154_173dup20 (p.Ala59Glnfs) duplication Pathogenic rs398124628 GRCh37 Chromosome X, 48649670: 48649689
2 PTEN NM_000314.6(PTEN): c.406T> C (p.Cys136Arg) single nucleotide variant Pathogenic rs786201044 GRCh37 Chromosome 10, 89692922: 89692922
3 TP53 NM_000546.5(TP53): c.636delT (p.Arg213Aspfs) deletion Pathogenic rs864309495 GRCh38 Chromosome 17, 7674895: 7674895

Copy number variations for Megakaryocytic Leukemia from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 158678 21 35304204 35704075 Loss RUNX1 Acute megakaryoblastic leukaemia

Expression for Megakaryocytic Leukemia

Search GEO for disease gene expression data for Megakaryocytic Leukemia.

Pathways for Megakaryocytic Leukemia

Pathways related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 CSF2 IL3 ITGA2B JAK3 KITLG PTEN
2
Show member pathways
13.03 CSF2 IL3 KITLG PTEN THPO
3
Show member pathways
13.01 CSF2 GATA1 IL3 ITGA2B JAK3 THPO
4
Show member pathways
12.78 IL3 ITGA2B KITLG PTEN THPO
5 12.41 ITGA2B KITLG PTEN RUNX1
6 12.3 IL3 ITGA2B JAK3 KITLG PTEN
7 12.29 GATA1 IL3 JAK3 KITLG MKL1 RUNX1
8 11.98 CSF2 IL3 RUNX1
9
Show member pathways
11.94 CSF2 IL3 JAK3 THPO
10
Show member pathways
11.92 IL3 KITLG PTEN
11
Show member pathways
11.88 CSF2 IL3 JAK3
12 11.78 GATA1 IL3 KITLG RUNX1 THPO
13 11.62 CSF2 IL3 ITGA2B KITLG THPO
14 11.47 IL3 ITGA2B KITLG THPO
15 11.34 CSF2 IL3 ITGA2B KITLG THPO
16 11.03 CSF2 IL3
17 10.78 CSF2 GATA1 IL3 ITGA2B KITLG RUNX1

GO Terms for Megakaryocytic Leukemia

Biological processes related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.83 CSF2 IL3 JAK3 KITLG
2 positive regulation of cell proliferation GO:0008284 9.8 CSF2 IL3 KITLG PTEN
3 peptidyl-tyrosine phosphorylation GO:0018108 9.65 CSF2 IL3 JAK3
4 MAPK cascade GO:0000165 9.56 CSF2 IL3 JAK3 KITLG
5 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.51 CSF2 GATA1
6 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 GATA1 IL3 KITLG
7 myeloid cell differentiation GO:0030099 9.46 GATA1 THPO
8 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.43 CSF2 IL3
9 positive regulation of leukocyte migration GO:0002687 9.4 ITGA2B KITLG
10 dendritic cell differentiation GO:0097028 9.37 CSF2 GATA1
11 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.16 KITLG THPO
12 positive regulation of DNA replication GO:0045740 9.13 CSF2 IL3 KITLG
13 embryonic hemopoiesis GO:0035162 8.8 GATA1 IL3 KITLG

Molecular functions related to Megakaryocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 CSF2 IL3 KITLG THPO
2 protein tyrosine kinase activity GO:0004713 9.43 CSF2 IL3 JAK3
3 growth factor activity GO:0008083 9.26 CSF2 IL3 KITLG THPO
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 CSF2 IL3 JAK3 KITLG

Sources for Megakaryocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....